Andrew John Armstrong, MD

Associate Professor of Medicine
Associate Professor in Pharmacology and Cancer Biology
Associate Professor in Surgery
Member of the Duke Cancer Institute
Campus mail Duke Box 103861, Durham, NC 27710
Phone (919) 668-8797
Email address

1. Predictors of sensitivity and clinical efficacy of therapies in advanced prostate cancer
2. Novel designs of clinical trials and pharmacodynamic/translational studies in prostate, kidney, bladder cancer
3. Pre-operative models for drug development of novel agents in human testing in prostate cancer
4. Novel therapies and drug development for prostate, renal, bladder, and testicular cancer
5. Design of rational combination therapies in men with metastatic hormone-refractory prostate cancer
6. PI3 kinase/mTOR inhibition in prostate cancer: mechanisms of sensitivity and resistance
7. Developing prognostic models for progression and survival in metastatic prostate cancer
8. Examining surrogate markers of mortality in metastatic prostate cancer
9. Clear cell and non-clear cell renal cell carcinoma: natural history, sensitivity to novel agents including mTOR and VEGF inhibition

In Their Words

Education and Training

  • Fellowship, Division Of Oncology/Hematology, Johns Hopkins University School of Medicine, 2003 - 2006
  • Internship/Residency, General Internal Medicine, University of Pennsylvania School of Medicine, 2000 - 2003
  • M.Sc., Johns Hopkins University, 2008
  • M.D., University of Virginia School of Medicine, 2000
  • B.S.E., Duke University, 1996



Humeniuk, MS, Gupta, RT, Healy, P, McNamara, M, Ramalingam, S, Harrison, M, George, D, Zhang, T, Wu, Y, and Armstrong, AJ. "Platinum sensitivity in metastatic prostate cancer: does histology matter?." Prostate cancer and prostatic diseases 21, no. 1 (April 2018): 92-99.

Full Text

Rathkopf, DE, Beer, TM, Loriot, Y, Higano, CS, Armstrong, AJ, Sternberg, CN, de Bono, JS, Tombal, B, Parli, T, Bhattacharya, S, Phung, D, Krivoshik, A, Scher, HI, and Morris, MJ. "Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial." JAMA oncology (March 8, 2018).

Full Text

Austin, RG, Huang, TJ, Wu, M, Armstrong, AJ, and Zhang, T. "Clinical utility of non-EpCAM based circulating tumor cell assays." Advanced drug delivery reviews 125 (February 2018): 132-142. (Review)

Full Text

Zhu, J, Armstrong, AJ, Friedlander, TW, Kim, W, Pal, SK, George, DJ, and Zhang, T. "Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond." Journal for immunotherapy of cancer 6, no. 1 (January 25, 2018): 4-. (Review)

Full Text

Armstrong, AJ, Antonarakis, ES, Taplin, M-E, Kelly, WK, Beltran, H, Fizazi, K, Dahut, WL, Shore, N, Slovin, S, George, D, Carducci, MA, Corn, P, Danila, D, Dreicer, R, Heath, E, Rathkopf, D, Liu, G, Nanus, D, Stein, M, Smith, MR, Sternberg, C, Wilding, G, Nelson, PS, Halabi, S, Kantoff, P, Clarke, NW, Evans, CP, Heidenreich, A, Mottet, N, Gleave, M, Morris, MJ, and Scher, HI. "Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet." Annals of oncology : official journal of the European Society for Medical Oncology 29, no. 1 (January 2018): 23-25.

Full Text

McNamara, M, Sweeney, C, Antonarakis, ES, and Armstrong, AJ. "The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation." Prostate cancer and prostatic diseases (December 20, 2017). (Review)

Full Text

Zhu, J, Tucker, M, Wang, E, Grossman, JS, Armstrong, AJ, George, DJ, and Zhang, T. "Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer." Clinical genitourinary cancer 15, no. 6 (December 2017): e1137-e1141.

Full Text

Taplin, M-E, Armstrong, AJ, Lin, P, Krivoshik, A, Phung, D, Parli, T, Tombal, B, and Beer, TM. "Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo." The Journal of urology 198, no. 6 (December 2017): 1324-1332.

Full Text

Zhang, T, and Armstrong, AJ. "The who, what, and how of cabazitaxel treatment in metastatic castration-resistant prostate cancer." Journal of Clinical Oncology 35, no. 28 (October 1, 2017): 3175-3177.

Full Text

Zhang, T, and Armstrong, AJ. "The Who, What, and How of Cabazitaxel Treatment in Metastatic Castration-Resistant Prostate Cancer." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 35, no. 28 (October 2017): 3175-3177.

Full Text